New drug information

- **Nuplazid™ (pimavanserin):** The Food and Drug Administration (FDA) approved Acadia Pharmaceuticals’ Nuplazid to treat psychosis (delusions and hallucinations) associated with Parkinson’s disease. Nuplazid is an atypical antipsychotic with a boxed alert to health care professionals about an increased risk of death associated with dementia-related psychosis treatment in the older patients.

- **Bevespi Aerosphere™ (glycopyrrolate and formoterol):** AstraZeneca received FDA approval for their combination of the long-acting muscarinic antagonist (LAMA) and the long-acting beta2 agonist (LABA) for treatment of chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere will compete against Novartis’ newly approved Utibron™ Neohaler as well as Anoro™ Ellipta® and Stiolto™ Respimat®.

- **Xtampza™ ER (oxycodone, extended-release):** Collegium received FDA approval for their abuse-deterrent extended-release formulation of oxycodone for the treatment of chronic pain.

New generics

- **Crestor® (rosuvastatin):** Allergan has launched its generic version of AstraZeneca’s Crestor for high cholesterol. Allergan will have 67 days of marketing exclusivity. After the exclusivity period, eight additional manufacturers are anticipated to launch product. According to IMS, Crestor had approximately $6.5 billion in sales over the past year.

- **Regimex® (benzphetamine):** The first generic of Wraser Pharmaceuticals’ Regimex for weight loss is now available.